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assessment of the exact nature of a pulmonary lesion
remains challenging. Even more challenging is the
determination of whether lymph node involvement and
P recise evaluation of the patient with a suspected pri-mary pulmonary malignant tumor continues to be a
problem for thoracic surgeons. Accurate preoperative
Objective: Positron emission tomography (PET), when used with the
intravenously administered radiopharmaceutical F-18 fluorodeoxyglu-
cose (FDG), has the potential to help in the evaluation of patients with
lung cancer because the radiopharmaceutical is concentrated by meta-
bolically active cells. We conducted a retrospective study of PET-FDG in
96 patients evaluated at our institution over the past 2 years for sus-
pected primary pulmonary neoplasms. PET-FDG results were com-
pared with the findings of computed tomographic scans on the same
patients. All patients underwent surgical exploration with or without
resection of the malignant tumors. Sites of potential malignancy were
subjected to biopsy and/or excision, with subsequent pathologic evalua-
tion. Results: A total of 96 patients with suspected or proven primary
pulmonary malignant disease were evaluated. Sixty-six patients had his-
tologically confirmed malignant tumors, and 30 had benign masses his-
tologically. PET-FDG had an accuracy of detecting malignancy in pul-
monary lesions of 92% (sensitivity 97%; specificity 89%). A total of 111
surgically sampled sites were from lymph nodes. PET-FDG was accu-
rate in predicting the malignancy of nodes in 91% of instances, where-
as computed tomography was correct in 64%. The sensitivity, specifici-
ty, and predictive accuracy of PET in detecting metastatic
lymphadenopathy in mediastinal lymph nodes were 98%, 94%, and
95%, respectively. PET-FDG also changed the M stage in 8 (12%)
patients (6 with and 2 without metastases). The 6 malignant (positive)
lesions were correctly identified by PET-FDG, and the 2 without tumor
were accurately predicted as benign (negative). Conclusion: These initial
results suggest that PET-FDG is highly accurate in identifying and stag-
ing lung cancer. PET-FDG also appears to be more accurate in detect-
ing metastatic mediastinal lymphadenopathy than computed tomo-
graphic scan. (J Thorac Cardiovasc Surg 1999;117:719-27)
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distant metastases exist at the time of presentation.
Several imaging techniques are currently available that
can help in the assessment of primary pulmonary
malignant tumors and their potential sites of metastatic
extension. Computed tomography (CT) is an estab-
lished imaging modality that has been used frequently
to evaluate pulmonary neoplasms since its inception.
Positron emission tomography (PET) is an emerging
imaging technique that shows great promise for evalu-
ating malignant pulmonary tumors and their metas-
tases. Like all diagnostic tests, both CT and PET have
their assets and liabilities.
CT is readily available and can be obtained in virtu-
ally every hospital. As with all imaging techniques, the
quality and quantity of information obtained is depen-
dent on the sophistication of the scanning apparatus
used. Modern CT equipment yields high-resolution
images of the chest in the axial orientation, which pro-
vide excellent anatomic definition of intrathoracic
structures. Studies that have evaluated the ability of CT
to predict involvement of mediastinal lymph nodes in
patients with lung cancer have yielded disappointing
results, because CT can predict nodal involvement only
by enlargement (diameter > 1 cm) or by morphologic
abnormality.1-3 Confirmation of nodal involvement by
the pulmonary malignancy, therefore, has required
mediastinoscopy and pathologic examination of biopsy
specimens.4,5 The inability of CT scan to recognize
metastatic disease in nodes of normal size has been
noted by several authors.6,7
PET scans have the ability to detect cancers by use of
the intravenously administered radiopharmaceutical F-
18 fluorodeoxyglucose (FDG), which is a D-glucose
analog that is concentrated by metabolically active cells
such as those found in malignant tumors.8,9 This tech-
nique is limited not only by the activity of the cells pre-
sent but also by physical volume of tumor, because
tumor volumes of less than 1 cm are more difficult to
detect due to PET resolution.10 Inflammatory process-
es can produce false positive results with PET.
Additionally, malignant tissue that is near ventricular
myocardium could be difficult to separate from the
heart, because metabolically active cardiac myocytes
concentrate FDG well.
To assess the efficacy of PET-FDG imaging in
patients with suspected primary pulmonary malignant
disease, we conducted a retrospective analysis of our
patients over a 2-year period. We focused on the abili-
ty of PET-FDG to define the nature of the pulmonary
lesion, to assess the status of each patient’s mediastinal
lymph nodes, and to detect distant metastases. In each
patient the results of the PET scan were compared with
those of the CT scan. The diagnostic efficacy of each
method was compared.
Methods
We reviewed the charts of all patients who were sent to the
Mary Babb Randolph Cancer Center of West Virginia
University School of Medicine for evaluation and treatment
of primary pulmonary malignant disease between October
1995 and October 1997. All patients who had some type of
diagnosed or suspected pulmonary malignant disease were
included. Those patients who had already started to receive
therapy for malignant disease before our initial evaluation
were excluded. All patients received a complete history and
physical examination. Standard chest radiographs (both pos-
teroanterior and lateral) were obtained on all patients if they
had not had such examinations performed within a month of
our initial evaluation. If the patients had had a chest CT scan
performed at another institution, the scan had to be a high-
resolution examination performed with intravenous contrast
medium and had to include the neck, thorax, and upper part
of the abdomen. If such a CT scan had not been obtained, one
was ordered as part of the initial evaluation. These CT scans
were performed with GE 9800 systems (GE Medical
Systems, Waukesha, Wis). Contrast (Hypaque 60 or
Omnipaque 300) consisted of 100 to 200 mL injected intra-
venously. Complete examinations were obtained both with
and without contrast medium. All PET scans were obtained
within 1 month of the CT scans.
All PET scans were performed at our institution with a GE
Advance Scanner (GE-1995). Informed consent was obtained
from all patients. The resolution of this scanner is 4.7 mm in
the transverse plane. Its field of view is 14.6 cm. Two distinct
scans were obtained: one emission and one transmission
scan. In the former, the scanner recorded, stored, and ana-
lyzed all the data generated from the positron activity emitted
from the injected FDG. PET scans on each patient were per-
formed in 3 to 4 different positions so that the field of view
of the scan included all tissues from the neck to the pelvic
floor. Emission scans were obtained with an acquisition time
of 5 minutes per field of view. Transmission scans were
obtained for 10 minutes in each position. The transmission
scan causes sequential cuts to be generated from a positron
beam, which is directed through the patient to generate atten-
uation data due to the body’s inherent tissue characteristics.
This allows the computer in the scanner to correct for back-
ground scatter and produce a corrected image. Each patient
was given an intravenous injection of 10 mCi of FDG after
having received nothing by mouth for at least 4 hours. An
emission scan of the patient’s body was then obtained 1 hour
after the injection of the FDG. A transmission scan was per-
formed directly after the emission scan. The scanner’s com-
puter collected all of the data from the patient’s emission scan
and corrected the images using the transmission attenuation
information to obtain clarified images in sequential axial pro-
jections. The data were then reexamined by the computer and
reformatted in the sagittal and coronal planes such that at
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least 35 images were created in each of the 3 orientations
(sagittal, coronal, and axial). Partial volume correction was
not performed. All of these projections were examined by the
radiologist and reports were generated for each patient stating
the likelihood of malignancy in the pulmonary mass, the
mediastinal nodes, and the possibility of distant metastases.
PET scan images were considered to be positive for malig-
nancy if there was focal hypermetabolic abnormality with
FDG uptake greater than background or mediastinal activity.
Quantitative analysis to compute standardized uptake values
(SUVs) was used to differentiate benign from malignant
lesions in equivocal cases. SUVs were computed by region of
interest analysis. SUVs greater than 3 were considered malig-
nant; this figure is similar to SUV values reported by other
investigators.7 Similar reports were generated for the CT
scans. The radiologist reading the CT scans was different
from the one interpreting the PET scans. All images were
analyzed qualitatively by visual analysis. The reader was not
aware of the histologic results or CT findings at the time of
scan interpretation. Data from the PET and CT scans were
tabulated and compared.
After a complete preoperative work-up, all patients under-
went surgical procedures to delineate the extent of their dis-
ease and conduct resections whenever possible. If their dis-
ease was deemed far advanced such that surgical resection
was not feasible, mediastinal nodes and distant sites of pre-
sumed metastases were sampled surgically. All tissues were
submitted for pathologic examination. The pathology reports
were used to assess the accuracy of the predictions made by
CT and PET scans.
Statistical method. Confidence intervals for the PET-FDG
and CT proportions (see Table III) are based on large-sample
symmetric results; that is, the normal approximation was
used to establish upper and lower 95% confidence bounds for
the various proportions reported.
Results
A total of 96 patients were evaluated and had com-
plete sets of data. The male/female ratio was 68:28.
The mean age was 65.9 years (range 43-80 years). Of
the 96 patients, 66 were found to have true malignant
tumors. The remaining 30 had various benign process-
es causing the masses in their lungs. Of the 96 pul-
monary lesions, 43 were smaller than 3 cm and 53 were
larger than 3 cm. The pathologic studies of the malig-
nant lesions showed that the vast majority were
non–small cell carcinomas (Table I). The largest num-
ber of these were adenocarcinomas. All but 2 of the
malignant tumors were detected and correctly predict-
ed by PET-FDG. The 2 that were missed were both
small bronchoalveolar cell carcinomas (1-2 cm), which
were included in the total adenocarcinoma group. In
reviewing the histologic slides after realizing that these
were both false negative tumors, we determined that
the lesions were very well differentiated and showed
few indications (eg, few mitotic figures per high-power
field) of increased metabolic activity.
Most of the benign lesions showed histologic pat-
terns consistent with healing inflammatory processes
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Table I. Histologic results of malignant pulmonary
tumors (n = 66)
No. of patients with diagnosis
Adenocarcinoma 35
Large cell 4
Poorly differentiated 1
Mixed pattern 9
Squamous cell carcinoma 10
Small cell carcinoma 2
Various other malignant tumors 5
Breast cancer 1
Neuroendocrine tumor 1
Thymic tumor 1
Lymphoma 2
Total patients 66
Table II. Histology of benign pulmonary lesions 
(n = 30)
Histologic type No. 
Localized fibrosis 10
Granuloma 8
Inflammation 7
Others 5
Sarcoidosis 1
Fungal 1
Lymphoid infiltrate 1
Pseudotumor 1
Cyst 1
Total patients 30
Three of the lesions were read as positive for malignancy by PET-FDG.
Table III. Comparison of CT and PET-FDG in assessing
true status of mediastinal lymph nodes (n = 111)
PET (95% CI) CT (95% CI)
Sensitivity 98% (93.5%-100%) 63% (50.5%-68.9%)
Specificity 94% (88.4%-99.5%) 60% (48.8%-72.4%)
Accuracy 95% (91.6%-99.4%) 61% (48.1%-76.1%)
Positive predictive 91% (83.9-99.5%) 64% (39.5%-85.9%)
value
All values are expressed with 95% confidence intervals (CI). PET, Positron
emission tomography; CT, computed tomography.
Sensitivity = (True positives)/(True positives + False negatives).
Specificity = (True negatives)/(True negatives + False positives).
Accuracy = (True positives + True negatives)/(True positives + True negatives
+ False positives + False negatives).
Positive predictive value = (True positives)/(True positives + False positives).
(Table II). The granulomas that were encountered
showed a wide range of inflammation and healing.
Some were quite organized and showed dense scarring.
Others appeared to be more active and possessed areas
of acute inflammation. Three of these were interpreted
by PET-FDG scans as being malignant (3 false posi-
tives). Since we culture our specimens routinely, the
culture results on these were obtained. Two showed no
growth even on prolonged selective cultures. One, how-
ever, did grow Cryptococcus neoformans organisms on
definitive cultures. SUVs in inflammatory false posi-
tive lesions were less than 5 and so were classified as
mild to moderate.
A total of 111 mediastinal lymph node stations (from
44 patients) were evaluated by PET-FDG and CT scans.
Pathologic examination showed that 45 stations had
malignant infiltration and 66 were benign. Only 8
lymph nodes were larger than 3 cm; the others were
smaller than 3 cm. After the pathology reports were
correlated with CT and PET-FDG data, the accuracy,
sensitivity, specificity, and predictive values for both
modalities were calculated (Table III). In 26 stations in
which CT scan predicted that lymph nodes that were
enlarged (>1 cm) would be malignant, PET-FDG cor-
rectly predicted that the nodes would be benign.
Similarly, in 15 lymph node stations that were predict-
ed to be benign by CT (<1 cm), PET-FDG accurately
predicted that they would contain metastases. Five of
16 nodal stations missed on CT showed N3 disease. All
told, PET-FDG changed preoperative staging for N in
31 (for a total of 41 stations) of 66 patients (47%). 
PET-FDG proved very capable of identifying unsus-
pected distant metastases and of determining the true
nature of suspected metastases. In 6 patients true dis-
tant metastases were confirmed when none was sus-
pected. In 4 patients bony metastases were identified.
The presence of bony metastases was confirmed on
biopsy (n = 1) or magnetic resonance imaging findings
(n = 3). In the remaining 2 patients, 1 adrenal mass and
1 cervical lymph node were identified as true distant
metastases. The adrenal mass was confirmed as a
metastasis by needle biopsy. Excision of the cervical
lymph node with subsequent pathologic examination
confirmed metastasis. In 2 other instances, lesions that
were suspected to be metastases were read by PET-
FDG as having no metastatic tumor activity. The adren-
al mass was subjected to subsequent needle biopsy and
was found on pathologic examination to be an adeno-
ma. The other suspected bony metastasis was detected
initially by a bone scan but was read as benign by PET-
FDG. The patient underwent resection of the primary
tumor and has subsequently undergone several bone
scans, all of which showed no suspicious activity in the
lesion previously thought to be a metastasis on the
basis of the initial bone scan.
Discussion
PET-FDG scan was very capable in our experience of
detecting true primary pulmonary malignant tumors.
Others have had similar results in evaluating primary
pulmonary malignant lesions with PET-FDG. Kubota
and associates10 studied 22 patients with noncalcifying
lung tumors and found that PET-FDG had a sensitivity
of 83%, a specificity of 90%, and an accuracy of pre-
dicting malignancy of 86%. Valk and associates6 stud-
ied 102 primary lung cancers in 99 patients and found
that better localization of primary lung tumors was
achieved when both transmission and emission scans
were used in conjunction. These authors, however, did
not report numbers on the accuracy of PET-FDG in
predicting the malignancy of suspected primary pul-
monary neoplasms. Scott and associates11 reported on
62 patients with lung tumors evaluated by PET-FDG.
The sensitivity and specificity of PET-FDG imaging
for differentiating benign from malignant primary lung
tumors were 93.6% and 80%, respectively. Accuracy in
this same study was 90%. The positive and negative
predictive values were 93.6% and 80%, respectively.
Hence PET-FDG can be expected to be approximately
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Fig 1. A PET-FDG imaging study (coronal view) demon-
strating intense FDG uptake in the hilar area of the right lung
in a patient with a primary lung cancer. There are also focal
areas of enhanced uptake consistent with metastatic lymph
nodes in the right infrahilar and left perihilar regions.
90% accurate in detecting the true malignant nature of
a primary pulmonary neoplasm. 
The problem of false negative results on PET-FDG
still exists, because the scanner has a finite lower limit
of spatial resolution and is dependent on the level of
metabolic activity inherent in the tumor cells.8,10 The
sophistication of the scanning apparatus we used
allows theoretic detection of tumors to 4.7 mm in great-
est diameter. This is better resolution than that reported
for earlier units, which had a theoretic lower limit of 1
cm.10 There were still 2 false negative results, however,
and these were in small nodules that had relatively qui-
escent malignant neoplasms. Differentiation of true
malignant neoplasms is more difficult for PET-FDG
when the metabolic activity of the neoplasm is low.12
Of all lung cancers, bronchioloalveolar cell carcinoma
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Fig 2. The plates presented in this figure demonstrate the utility of collecting PET images in multiple projections.
A, A selected cut from a chest CT scan taken in a 62-year-old woman who had a primary pulmonary malignant
tumor at the hilum of the left lung. B, A selected coronal image in the same patient shows a prominent left hilar
carcinoma just above the area of intensity generated by the ventricular myocardium. A metastatic nodule is appar-
ent in the right paratracheal region near the head of the clavicle. The area of intense activity low in the projection
represents residual metabolized FDG present in the patient’s urinary bladder. C, This parasagittal view in the
same patient shows part of the metabolic activity recorded from PET-FDG in the heart and bladder, as well as the
metastatic nodes in the superior mediastinum. Most important, it detected a metastatic bone lesion that was a pre-
viously unsuspected metastasis in the spine, seen at the far right of the image.
A
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appears to be the most likely to cause false negative
readings on PET-FDG because of its relatively low
metabolic activity.11 In one study, 3 false negative read-
ings on PET-FDG were obtained: 2 were on tumor
masses smaller than 1 cm in diameter and the third was
on a bronchioloalveolar carcinoma.11 One recent study
by Kim and colleagues13 has even suggested that peak
SUVs should be used in evaluating all malignant pul-
monary lesions. In their study conducted on 48
patients, they found that the mean peak SUV for bron-
chioloalveolar carcinoma was significantly less than
those values recorded for squamous cell carcinoma and
for adenocarcinoma.13 Unfortunately, those authors did
not include any data on peak SUVs on patients who had
granulomatous lesions in their lungs. Such a compari-
son would be helpful inasmuch as the SUVs on PET-
FDG may well be comparable with those seen for rela-
tively low-grade carcinomas.
In our study PET-FDG read 3 benign lesions as
malignant. These false positive results were all due to
granulomatous inflammatory processes. As noted pre-
viously, acute and indolent processes can concentrate
PET-FDG due to the increased metabolic activity seen
in the inflammatory cells.14 This may occur since FDG
is known to accumulate in macrophages in granulation
tissue that may surround an inflammatory or a neoplas-
tic process.15,16 Others have noted that histoplasmosis
and related organisms are particularly prone to causing
false positive PET-FDG readings.11 Hypermetabolism
has been described in both inflammatory and granulo-
matous lesions to a degree that will cause false positive
PET-FDG determinations in aspergillosis and active
tuberculosis as well.17,18
One recent study addressed the relative mean SUVs
between benign and malignant pulmonary lesions.19 In
this study 59 patients with cancer had a significantly
higher mean standardized uptake ratio than 28 patients
with benign disease. (8.01 ± 6.09 for malignant vs 2.99
± 0.49 for benign). Most notably, these same authors
showed that in their series PET-FDG was able to iden-
tify correctly all intrathoracic recurrences in the
patients they studied with primary pulmonary malig-
nant tumors.
The superiority of PET-FDG over CT in determining
the correct status of mediastinal lymph nodes in
patients who have primary pulmonary malignant dis-
ease is well established. Several authors have published
data that support our findings.6,7,11,20 Valk and associ-
ates6 found that the sensitivity and specificity for PET-
FDG in detecting N2 disease were 83% and 94%,
respectively, whereas the comparable figures for CT
were 63% and 73%, respectively. Steinert and col-
leagues7 found that the sensitivity of PET and CT was
89% and 57%, respectively, for the staging of N2 or N3
disease in mediastinal nodes. These same authors
found that specificity for N2 and N3 disease was 99%
for PET and 94% for CT, and the positive predictive
values for these 2 imaging modalities were 96% and
76%, respectively. Scott and colleagues11 believed that
PET-FDG was a highly accurate noninvasive method
for identifying malignant lung tumors but had to have
the data from prospective studies before its value in
assessing N2 disease could be determined.
Vansteenkiste and associates20 believed that the results
of PET-FDG were superior when they were used in
conjunction with CT data. Currently, most investigators
think that PET-FDG is superior to CT but that the two
should be used together to achieve the highest possible
accuracy in assessing the status of mediastinal lymph
nodes.20 After collating the CT and PET data presented
herein, we also found that the accuracy of the two tech-
niques improves when the information from CT and
PET are considered in concert. 
We found PET-FDG quite helpful in detecting
unknown metastatic sites. Other institutions have had
similar experiences.6,21,22 Using PET-FDG, Valk and
colleagues6 found 11 (11%) patients with previously
unsuspected distant metastasis, with no demonstrated
false positive results. One recent report stated that PET
had an accuracy of 96% in the detection of M stage in
patients with primary pulmonary malignant tumors.21
Detection of unsuspected cancer in scalene lymph
nodes has been reported by others.22 In all, we believe
that PET-FDG has a large potential for detecting unsus-
pected metastatic lesions caused by primary pulmonary
malignant tumors. More data need to be available
before firm guidelines can be established. In our study
helical CT scanning was not performed. It is possible
that use of helical CT may improve sensitivity.
One place wherein PET-FDG may be less useful in
detecting metastases is the perinephric tissues, because
FDG is concentrated by the kidneys and excreted in the
urine. In our own experience we have found it difficult
to distinguish metastatic implants from renal parenchy-
ma. As reported in this work, we think that PET-FDG
is quite capable of determining the true nature of mass-
es found in the adrenals in patients with primary pul-
monary malignant tumors. Others share this opinion.23
In a study that evaluated the ability of PET-FDG to
determine the true nature of masses in patients with
cancer, 24 adrenal masses were evaluated in 20
patients.23 The authors concluded that PET-FDG
helped determine the correct differentiation between
benign and malignant lesions in the adrenals.23
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Certainly more data are needed for patients with pri-
mary pulmonary malignant disease, but the initial data
suggest that PET-FDG may be very helpful in deter-
mining the true nature of potential adrenal metastases.
In summary, PET-FDG has a high degree of sensitiv-
ity, specificity, and accuracy in denoting the true nature
of a pulmonary mass. PET appears to be superior in
delineating the true involvement of mediastinal lymph
nodes by primary pulmonary malignant disease. PET is
also very capable of identifying the presence of occult
metastases. False positive results may be obtained by
PET from lesions that have a high degree of metabolic
activity, such as active granulomatous lesions. False
negative PET results may occasionally occur in patients
who have malignant tumors with cells that are less
metabolically active. In all, we believe that PET scan-
ning is an important tool in evaluating patients with sus-
pected lung cancer, because it gives important informa-
tion that allows more accurate preoperative staging and
could result in improved patient management.
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Discussion
Dr Joel D. Cooper (St Louis, Mo). Dr Graeber, I want to
congratulate you and your coauthors for a very important
paper. 
Years ago when I was in Toronto at the dawn of the mag-
netic resonance imaging era, we evaluated magnetic reso-
nance imaging for lung cancer in the hopes that it would
reflect not just the size of lymph nodes but perhaps their con-
tent. We used to refer to it as a “magnetic biopsy.” However,
it was of no additional value to CT in the staging of lung can-
cer because it detected physical presence, not content. Thus it
was with some skepticism that we viewed the advent of PET
with its proposed ability to do a metabolic biopsy.
Our experience to date, mainly with esophageal cancer and
more recently with lung cancer, has turned our skepticism
into enthusiasm. We previously reported, for esophageal can-
cer, exactly the same type of experience that you have reported
with lung cancer. In about 100 consecutive cases of
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esophageal cancer, only 2 tiny 1- to 2-mm mucosal lesions
were undetected. All other primary sites were detected. 
As in your report, metastases, unsuspected on the basis of
CT scan, were detected and proven by biopsy. Also as in
your report, staging was changed in about 25% of cases by
the addition of PET to the other standard techniques for stag-
ing. Our experience with the use of PET scanning for lung
cancer has been less focused and less rigorous, perhaps be-
cause we have just begun to gain experience. However, I
share your enthusiasm for it. As a long-time proponent of
mediastinoscopy before thoracotomy for all patients with
lung cancer, I believe the day will come when a combination
of a negative PET and a negative CT will preclude the need
for doing mediastinoscopy. 
I would like to share a couple of caveats to emphasize points
you made and ask a few questions. As you have demonstrated,
the image in the PET scan relates not to the physical size of
the lesion but to its intensity. A bright image may be large, but
it has nothing to do with the actual size of the lesion. Because
of this, it will eclipse any surrounding or adjacent lymph
nodes, which cannot be detected. Thus adjacent nodes cannot
be seen in esophageal cancer, and I would propose that for
hilar lesions of the lung, adjacent lymph nodes probably
would not be seen. Is this also your impression? 
Second, there is no clear-cut definition of what constitutes
a positive PET scan. We find that the assessment is observer-
dependent, depending on the experience of the observer. Do
you find that to be true as well? False negatives at the prima-
ry site with lung cancer in our experience have occurred in
exactly the circumstances you have mentioned, namely, slow
growing bronchioloalveolar carcinomas with a low metabolic
rate. 
Have your results in this study yet changed your approach
to the use of mediastinoscopy for the diagnosis of metastatic
nodes? Is the PET scan in your institution read in conjunction
with the CT scan? If so, this does not replace the CT scan, and
I believe your manuscript makes that point quite clearly. 
Finally, you found 4 bony metastatic lesions. Was biopsy or
clinical follow-up used to confirm these findings?
Dr Graeber. Thank you, Dr Cooper. I think it is evident
from Dr Cooper’s comments and from mine that we are still
in the middle of the learning curve regarding use of PET. It is
difficult to define masses that are close together, and indeed
we have had difficulty in defining masses that may be very
close to the active myocardium. We have also had difficulty
in finding masses that are present within the renal parenchy-
ma, because the dye is concentrated in this area.
The PET scan is dependent on the observer and on an eval-
uation process. Articles are being presented which suggest
that the SUVs, which take the actual counts and then take out
the background information, are now being taken from
lesions and being compared. One article in the Journal of
Radiology compared SUVs and found a statistically signifi-
cant difference between benign lesions, such as granulomas
that we found, and bronchoalveolar cell carcinomas. We are
starting to use the SUVs. 
We have changed our approach to mediastinoscopy some-
what, but we still need more information, and we have start-
ed on a prospective study to get that information. 
We do use both the CT scan and the PET scan together. We
gain more information from using both, and we do not believe
in disregarding good information. Others have just started to
report this in the radiologic literature and have shown
increased accuracy by using both scans versus using each
individually with separate radiographers reading the scans.
Also, we did confirm our bone biopsies in all but one instance.
The other instance was confirmed by serial bone scans, which
showed negativity, and that was in the benign lesion.
Dr Michael A. Grosso (Browns Mills, NJ). We were just
referred a patient who had a negative PET scan, with a 1.5-
cm lesion in the right upper lobe. She was counseled by her
pulmonologist not to undergo any invasive testing but to wait
another 6 months or longer and have the scan repeated. She
was uncomfortable with this advice. We resected the lesion,
and it was an adenocarcinoma of the lung. 
I wish to inject a note of caution, not so much about the fal-
libility of the scan, but about some of the advice that may be
given to patients on the basis of the results of the scans.
Dr Graeber. I agree with your caution. I have had similar
experiences. We are not yet at a point where we can make
those determinations. If the scan results were negative in one
of my patients, I, too, would obtain a biopsy of the lesion and
send it to a pathologist. 
Commentary
The current study by Graeber and associates provides
further compelling support for the use of FDG-PET
imaging in diagnosing and staging lung cancer. These
investigators, like others, have elucidated the limited
role of conventional anatomic imaging, which de-
scribes the location and morphologic characteristics of
primary lung lesions, as opposed to PET, which pro-
vides metabolic information, in evaluating patients
with possible lung cancer. PET helps to differentiate
benign from malignant abnormalities indeterminate by
CT. In fact, the authors of this study found PET to be
92% accurate in making this distinction. The implica-
tion for patients with an indeterminate pulmonary
abnormality is not trivial. In some series, up to 50% of
these abnormalities are proved to be benign after surgi-
cal resection. A negative PET obviates the need for this
unnecessary intervention in many cases.
Similarly, hilar and mediastinal lymph node size and
morphology as assessed by CT is clearly a suboptimal
staging procedure with sensitivities and specificities
about 60%. In the current and prior studies, PET was
significantly more accurate than CT (91% vs 64%) as a
predictor of nodal disease. Ideally, further investiga-
tions will elucidate which surgical patients can go
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directly to primary resection and which patients will
require lymph node sampling.
In describing other findings on the staging PET
study, the authors found 12% of patients had a change
in their M stage as compared with conventional imag-
ing. This resulted in more accurate overall staging and
thus more appropriate patient treatment.
Although this and other series have demonstrated the
clinical utility of FDG-PET in complementing con-
ventional studies, perhaps more important is the en-
tirely new direction PET has taken diagnostic radiology.
It is a model system for molecular imaging, and as
more is understood about basic tumor biology, we will
be able to incorporate metabolic, biochemical, or even
genetic changes of tumors in the effort to develop a
noninvasive tumor profile. These tumor characteristics
detailed by imaging should provide essential diag-
nostic information with prognostic and therapeutic
implications.
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